EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) and privately held Serenity Pharmaceuticals today announced that they are collaborating on an intranasal drug candidate for a urology indication. New York-based Serenity’s drug candidate will be delivered using CPEX’s patented drug delivery technology. Serenity believes the drug targets a potential worldwide market of $2 - $3 billion.
